Topical Agents Containing Magnesium Sulfate & Wound Healing in the Rat Model

NCT ID: NCT04886882

Last Updated: 2021-05-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-22

Study Completion Date

2021-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An experimental study examining wound healing in 5 different groups on 30 rats.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Magnesium topically increases collagen synthesis and angiogenesis, providing faster and higher quality wound healing. In addition, with its analgesic effect, it will also eliminate the pain sensation caused by the wound and increase the quality of life of the patient whose skin integrity is impaired.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wound Heal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group placebo

Isotonic solution will be administered daily to 6 female rats.

Group Type PLACEBO_COMPARATOR

placebo comparator

Intervention Type OTHER

solution containing 0.9 % sodium chlorine

Group sham

Base cream to be applied twice a day to 6 female rats.

Group Type SHAM_COMPARATOR

sham comparator

Intervention Type OTHER

vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water

Group %1 mgso4

Cream containing 1% MgSO4 will be applied twice a day to 6 female rats.

Group Type EXPERIMENTAL

Experimental drug 1

Intervention Type OTHER

A cream containing 10 % MgSO4.vaseline, beeswaxpolyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water

Group %10 MgSO4

Cream containing 10% MgSO4 will be applied twice a day to 6 female rats.

Group Type EXPERIMENTAL

Experimental drug 2

Intervention Type OTHER

A cream containing 10 % MgSO4.vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water

Group positive control

Cream containing centella asiatica will be applied twice a day to 6 female rats.

Group Type ACTIVE_COMPARATOR

Centella asiatica

Intervention Type DRUG

A cream containing Centella asiatica

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

placebo comparator

solution containing 0.9 % sodium chlorine

Intervention Type OTHER

sham comparator

vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water

Intervention Type OTHER

Experimental drug 1

A cream containing 10 % MgSO4.vaseline, beeswaxpolyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water

Intervention Type OTHER

Experimental drug 2

A cream containing 10 % MgSO4.vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water

Intervention Type OTHER

Centella asiatica

A cream containing Centella asiatica

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy rats between ages of 8- 12 weeks

Exclusion Criteria

* weight loss of more than 15% of body weight
Minimum Eligible Age

8 Weeks

Maximum Eligible Age

12 Weeks

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istanbul Kent University

OTHER

Sponsor Role collaborator

Başakşehir Çam & Sakura City Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Başakşehir Çam Ve Sakura Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SakuraDermatology1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.